Malignant Pleural Effusion Global Market Report 2025
상품코드:1730939
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
악성 흉수 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 61억 7,000만 달러로 성장할 전망이며, CAGR 6.8%로 성장이 예측됩니다. 예측 기간 동안의 성장은 헬스케어 인프라 확대, 정부 지원 증가, 암 생존자 증가, 재가 케어 수요 확대, 리퀴드 바이옵시의 진보 등에 기인할 것으로 보입니다. 이 기간 주요 동향으로는 이미징 툴에서의 인공지능 통합, 표적 암 치료의 진전, 흉막 유착술의 진보, 바이오마커의 개선, 신규 치료제의 임상시험 확대 등을 들 수 있습니다.
폐암 환자 수 증가가 악성 흉수 시장의 성장을 견인할 것으로 예측됩니다. 폐암은 폐에서 이상 세포의 제어 불가능한 증식을 특징으로 하는 질환으로 종양을 형성하거나 정상적인 폐 기능을 파괴합니다. 담배에 포함된 유해한 화학물질에 장기간 노출되면 폐조직에 손상을 주고 유전자 변이를 일으키며 암세포의 무질서한 증식을 촉진하기 때문에 폐암 발병 위험이 크게 높아집니다. 악성 흉수는 흉막강 내 종양 확산을 조장함으로써 진행된 폐암의 진행을 알리고 호흡 기능을 악화시키며 예후를 나쁘게 합니다. 예를 들어 2023년 1월 미국을 거점으로 하는 전문기관인 미국암협회는 2022년 폐암 및 기관지암 신규 사례 수는 추정 23만 6,740례, 추정 사망 수는 13만 180례였다고 보고했습니다. 2023년에 대해서는 신규 사례 수는 23만 8,340명으로 증가하였고, 사망자 수는 12만 7,070명으로 약간 감소한 것으로 평가되고 있습니다. 이러한 폐암 환자의 증가가 악성 흉수 시장의 성장을 견인하고 있습니다.
헬스케어 인프라 개선은 악성 흉수 시장의 성장을 더욱 촉진할 것으로 예측되고 있습니다. 헬스케어 인프라에는 병원, 진료소, 의료기기, IT 시스템, 의료 종사자 등 헬스케어 서비스를 제공하는 데 필요한 물리적, 기술적, 조직적 요소가 포함됩니다. 헬스케어 인프라의 강화는 보다 나은 질병 관리의 필요성에 의해 추진되며, 접근성, 효율성, 케어의 질 향상을 목표로 하고 있습니다. 첨단 의료기술, 시설이 잘 갖춰진 의료시설, 전문적인 케어에 대한 접근을 가능하게 함으로써 보다 나은 진단, 치료, 악성 흉수 관리를 지원하고 궁극적으로는 환자의 전귀 개선으로 이어집니다. 예를 들어 2023년 5월 미국 비영리단체인 미국헬스케어협회는 미국 병원 수가 전년 6,093에서 6,129로 0.591% 증가했다고 보고했습니다. 이러한 헬스케어 인프라 향상이 악성 흉수 시장 성장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 악성 흉수 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 악성 흉수 시장 : 성장률 분석
세계의 악성 흉수 시장 실적 : 규모 및 성장(2019-2024년)
세계의 악성 흉수 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 악성 흉수 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 악성 흉수 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
전신요법
치료적 흉강 천자
흉강 배수 및 흉막 유착술
유치 흉막 카테터
세계의 악성 흉수 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
흉수 세포 진단
면역조직화학검사
화상 검사
흉막 흉곽증
흉막경 검사
흉막 생검
세계의 악성 흉수 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
외래 진료소
기타 최종 사용자
세계의 악성 흉수 시장 : 전신 요법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
화학 요법
표적 요법
면역 요법
세계의 악성 흉수 시장 : 치료적 흉강 천자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단회 흉강 천자
흉강 천자 반복
세계의 악성 흉수 시장 : 흉강 배수 및 흉막 유착술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
화학적 흉막 유착술
기계적 흉막 유착술
생물학적 흉막 유착술
세계의 악성 흉수 시장 : 유치 흉막 카테터 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
터널형 흉막 카테터
비터널형 흉막 카테터
제7장 지역별 및 국가별 분석
세계의 악성 흉수 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 악성 흉수 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
악성 흉수 시장 : 경쟁 구도
악성 흉수 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis International AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Gilead Sciences Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Amgen Inc.
Medline Industries LP
Becton Dickinson and Company
Cook Medical LLC
Merit Medical Systems Inc.
Argon Medical Devices Inc.
B Braun SE
Simcere Pharmaceutical Group Limited
pfm medical AG
Redax SpA
Wuhan YZY Biopharma Co. Ltd.
Rocket Medical plc
Genelux Corporation
Gongwin Biopharm Holdings Co. Ltd.
Ewimed GmbH
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
악성 흉수 시장(2029년) : 새로운 기회를 제공하는 국가
악성 흉수 시장(2029년) : 새로운 기회를 제공하는 부문
악성 흉수 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Malignant pleural effusion (MPE) is the buildup of fluid in the pleural space caused by the presence of cancer cells, usually due to metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, resulting in increased vascular permeability and impaired lymphatic drainage.
The main treatment options for malignant pleural effusion include systemic therapy, therapeutic thoracentesis, thoracic drainage and pleurodesis, and the placement of an indwelling pleural catheter. Systemic therapy is a cancer treatment that circulates through the bloodstream to target and eliminate cancer cells throughout the body. Diagnosis is typically performed using methods such as pleural fluid cytology, immunohistochemical tests, imaging tests, pleural thoracentesis, pleuroscopy, and pleural biopsy. These treatments and diagnostic procedures are utilized by various end users, including hospitals, ambulatory clinics, and other healthcare facilities.
The malignant pleural effusion market research report is one of a series of new reports from The Business Research Company that provides malignant pleural effusion market statistics, including the malignant pleural effusion industry global market size, regional shares, competitors with the malignant pleural effusion market share, detailed malignant pleural effusion market segments, market trends, and opportunities, and any further data you may need to thrive in the malignant pleural effusion industry. This malignant pleural effusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing adoption of indwelling pleural catheters, a greater focus on palliative care, a rise in clinical trials, higher reimbursement rates, and the growing prevalence of metastatic malignancies.
The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, increased government support, a rising number of cancer survivors, growing demand for home-based care, and advancements in liquid biopsy. Key trends during this period include the integration of artificial intelligence in imaging tools, progress in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and the expansion of clinical trials for novel therapeutic agents.
The increasing number of lung cancer cases is expected to drive the growth of the malignant pleural effusion market. Lung cancer is a disease marked by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and disrupt normal lung function. The rise in lung cancer cases is largely due to smoking and tobacco use, as long-term exposure to harmful chemicals in cigarettes damages lung tissues, causes genetic mutations, and encourages the uncontrolled growth of cancerous cells, significantly raising the risk of developing the disease. Malignant pleural effusion signals advanced lung cancer progression by aiding the spread of tumors within the pleural cavity, which worsens respiratory function and leads to a poorer prognosis. For example, in January 2023, the American Cancer Society, a U.S.-based professional organization, reported that in 2022, there were an estimated 236,740 new cases of lung and bronchus cancer, with 130,180 estimated deaths. For 2023, new cases are expected to rise to 238,340, with deaths expected to decrease slightly to 127,070. This increase in lung cancer cases is driving the growth of the malignant pleural effusion market.
The improvement of healthcare infrastructure is anticipated to further fuel the growth of the malignant pleural effusion market. Healthcare infrastructure encompasses the physical, technological, and organizational elements required for delivering healthcare services, such as hospitals, clinics, medical equipment, IT systems, and healthcare personnel. The enhancement of healthcare infrastructure is driven by the need for better disease management and aims to improve accessibility, efficiency, and care quality. It supports better diagnosis, treatment, and management of malignant pleural effusion by granting access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately leading to improved patient outcomes. For instance, in May 2023, the American Health Care Association, a U.S.-based nonprofit organization, reported a 0.591% increase in the number of hospitals in the U.S., rising from 6,093 in the previous year to 6,129. This improvement in healthcare infrastructure is contributing to the growth of the malignant pleural effusion market.
Companies in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that designs drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly applied to conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For example, in September 2022, RS Oncology, LLC, a U.S.-based biotechnology company, initiated the MITOPE clinical trial, a first-in-human Phase 1/2 study conducted in the United Kingdom. This trial is evaluating RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.
Major players in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH.
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant pleural effusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the malignant pleural effusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The malignant pleural effusion market consists of revenues earned by entities by providing services such as biopsy and cytology testing, chemotherapy and targeted therapy, and pleurodesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant pleural effusion market also includes sales of chest drainage systems, pleural access kits, and imaging-guided drainage equipment, and thoracentesis devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Malignant Pleural Effusion Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on malignant pleural effusion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for malignant pleural effusion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant pleural effusion market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Systemic Therapy; Therapeutic Thoracentesis; Thoracic Drainage And Pleurodesis; Indwelling Pleural Catheter
3. Malignant Pleural Effusion Market Trends And Strategies
4. Malignant Pleural Effusion Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Malignant Pleural Effusion Growth Analysis And Strategic Analysis Framework
5.1. Global Malignant Pleural Effusion PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Malignant Pleural Effusion Market Growth Rate Analysis
5.4. Global Malignant Pleural Effusion Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Malignant Pleural Effusion Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Malignant Pleural Effusion Total Addressable Market (TAM)
6. Malignant Pleural Effusion Market Segmentation
6.1. Global Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systemic Therapy
Therapeutic Thoracentesis
Thoracic Drainage And Pleurodesis
Indwelling Pleural Catheter
6.2. Global Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pleural Fluid Cytology
Immunohistochemical Tests
Imaging Tests
Pleural Thoracentosis
Pleuroscopy
Pleural Biopsy
6.3. Global Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Clinics
Other End Users
6.4. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
6.5. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Therapeutic Thoracentesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Time Thoracentesis
Repeated Thoracentesis
6.6. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Thoracic Drainage And Pleurodesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemical Pleurodesis
Mechanical Pleurodesis
Biological Pleurodesis
6.7. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Indwelling Pleural Catheter, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tunneled Pleural Catheter
Non-Tunneled Pleural Catheter
7. Malignant Pleural Effusion Market Regional And Country Analysis
7.1. Global Malignant Pleural Effusion Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Malignant Pleural Effusion Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
